About Our Program
The department of Translational Molecular Medicine has trained over 70 M.D. and Ph.D fellows, and has graduated 6 Ph.D’s. The department concentrates on innovative translational approaches in molecular oncology and is well known for its pioneering translational studies on “liquid biopsies” involving circulating tumor cells (CTC), as well as cell-free nucleic acids (cfNA) assessment in multiple types of solid tumors.
Current program directions consist of studying epigenetic mechanisms regulating solid tumor progression that includes primary and metastatic brain tumors, as well as pharmogenomic and immunogenomic based prediction of response to therapy. The department has strong collaborative relationships with academic institutes and pharma/biotech industries with oncology programs globally, and its past fellows have had a remarkable publication record in translational molecular oncology.